Home LiteratureArticle Details
PMID: 16932688 Published · ppublish English Journal Article Research Support, N.I.H., Intramural Review

Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies.

Nature clinical practice. Rheumatology ·Vol. 2 ·No. 4 ·2006-04-00 ·Pages 219-27

Dalakas MC

Abstract

The signaling pathways involved in the immunobiology of polymyositis, dermatomyositis, and inclusion-body myositis are outlined in this Review, which is based on research performed during the past 10 years. In dermatomyositis, the complement cascade is activated and the expression of cytokines and chemokines is upregulated. In polymyositis and inclusion-body myositis, autoinvasive CD8+ T cells are clonally expanded. This T-cell subset possesses conserved amino-acid sequences in complementarity-determining region 3 of the T-cell receptor and, via the perforin pathway, exerts a myotoxic effect on muscle fibers that express major histocompatibility complex (MHC) class I molecules. In all inflammatory myopathies, molecules associated with T-cell transmigration and cytokine signaling, as well as chemokines and their receptors, are strongly expressed by endothelial and inflammatory cells. Early in the pathogenesis of polymyositis and inclusion-body myositis, expression of MHC class I molecules on muscle fibers is upregulated, even in the absence of autoinvasive CD8+ T cells. Emerging data indicate that such continuous upregulation of the expression of MHC class I molecules on muscle fibers leads to an endoplasmic reticulum stress response, intracellular accumulation of misfolded glycoproteins, and activation of nuclear factor kappaB pathways, which can further stimulate formation of MHC class I-CD8 complexes, resulting in a self-sustaining inflammatory response. Advances in our understanding of the signaling pathways involved in the pathogenesis of these inflammatory myopathies are expected to result in the identification of novel therapeutic targets for these diseases.

MeSH Terms
Disease Progression Humans Immunosuppressive Agents/therapeutic use Myositis/drug therapy,immunology,metabolism Signal Transduction/immunology T-Lymphocyte Subsets/immunology
Chemicals
Immunosuppressive Agents
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Dalakas Marinos C
Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1382, USA. dalakasm@ninds.nih.gov
Article Info
Journal
Nature clinical practice. Rheumatology
Abbr.
Nat Clin Pract Rheumatol
ISSN
1745-8382
Published
2006-04-00
Pages
219-27
Language
English
Region
United States
NLM ID
101261802
Subset
IM
Grants
Intramural NIH HHS · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com